About Phio Pharmaceuticals Corp. - Common Stock (PHIO)
Phio Pharmaceuticals Corp is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company specializes in leveraging its proprietary delivery platform to enhance the effectiveness of immune-based therapies, particularly in the area of adoptive cell therapy. By utilizing their unique technology, Phio aims to create treatments that can empower the body’s immune system to better target and destroy cancer cells, ultimately improving patient outcomes and offering new hope in the fight against various types of cancer. Read More
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company pioneering a new era in precision oncology. By combining deep genetic insight with targeted molecular design, Aprea is advancing therapies that exploit cancer-specific vulnerabilities — aiming to outsmart tumor biology while preserving healthy tissue and improving patient quality of life.
Get a pulse on the US markets on Monday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company...
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...
Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile...
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company...
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough,...
